# Risk: __Inadequate vaccine efficacy__ (PBN__Risk_1911)

## Property: has_RiskSubject

* [vaccinated individuals](../Stakeholder/PBN__Stakeholder_1293)

## Property: has_RiskISO_Impact

* [Safety and security](../RiskISO/PBN__RiskISO_Purpose_5)

## Property: has_RiskSource

* [pilz_contributions_2022](../Article/PBN__Article_245)

## Property: has_RiskName

Decreased overall protection against COVID-19 re-infections.

## Property: has_RiskHealth

* [physical](../RiskHealth/PBN__RiskHealth_0)

## Property: has_RiskGBN

* [Yes](../RiskGBN/PBN__RiskGBN_1)

## Property: has_RiskTechnology

* [vaccine development and improvement technologies](../Technology/PBN__Technology_1307)

## Property: has_RiskOwner

* [vaccine manufacturers](../Stakeholder/PBN__Stakeholder_1294)
* [healthcare providers](../Stakeholder/PBN__Stakeholder_121)

## Property: has_RiskType

* [technological](../RiskType/PBN__RiskType_5)

## Property: has_RiskDescription

Waning efficacy of vaccines against re-infections.

## Property: has_RiskISO_Purpose

* [Safety and security](../RiskISO/PBN__RiskISO_Impact_0)

## Property: has_RiskMitigation

* [Improve vaccine efficacy through research and development.](../RiskMitigation/PBN__RiskMitigation_2512)

